Cargando…

Remission of Refractory Membranous Nephropathy by Low-dose Rituximab: A Case Report

Detalles Bibliográficos
Autores principales:	Wang, Xiao-Pei, Hu, Zhang-Xue, Guo, Dong-Yang, Tao, Ye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Clinical Practice
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819311/ https://www.ncbi.nlm.nih.gov/pubmed/26996486 http://dx.doi.org/10.4103/0366-6999.178967

Ejemplares similares

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021)

Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study
por: Chen, Xian, et al.
Publicado: (2023)

Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience
por: Bagchi, Soumita, et al.
Publicado: (2018)

Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2022)

A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up
por: Zhou, Xu-Jie, et al.
Publicado: (2018)

Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience
por: Wang, Yao-Wei, et al.
Publicado: (2023)

Rituximab for the treatment of refractory anti-glomerular basement membrane disease
por: Yang, Xue-Fen, et al.
Publicado: (2022)

Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience
por: Katsuno, Takayuki, et al.
Publicado: (2017)

Rituximab in Membranous Nephropathy
por: Gauckler, Philipp, et al.
Publicado: (2021)

CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy
por: Ramachandran, Raja, et al.
Publicado: (2016)

Membranous nephropathy with systemic light-chain amyloidosis of remission after rituximab therapy: A case report
por: Zhang, Jiao, et al.
Publicado: (2023)

Serum Albumin at Partial Remission Predicts Outcomes in Membranous Nephropathy
por: Lee, Taewoo, et al.
Publicado: (2020)

Case Report: Complete Remission of C1q Nephropathy Treated With a Single Low-Dose Rituximab, a Reality or Coincidence?
por: Ma, Rui, et al.
Publicado: (2021)

Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy
por: Bandak, Ghassan, et al.
Publicado: (2014)

Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
por: Bonilla-Abadía, Fabio, et al.
Publicado: (2014)

Remission Achieved in Refractory Advanced Takayasu Arteritis Using Rituximab
por: Ernst, D., et al.
Publicado: (2012)

Membranous Nephropathy: Pilot Study of a Novel Regimen Combining Cyclosporine and Rituximab
por: Waldman, Meryl, et al.
Publicado: (2016)

Treatment with rituximab in idiopathic membranous nephropathy
por: Fiorentino, Marco, et al.
Publicado: (2016)

Rituximab in patients with membranous nephropathy and kidney insufficiency
por: Guo, Yanhong, et al.
Publicado: (2022)

Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
por: Cortazar, Frank B., et al.
Publicado: (2017)

Rituximab in Patients With Phospholipase A2 Receptor–Associated Membranous Nephropathy and Severe CKD
por: Hanset, Nicolas, et al.
Publicado: (2019)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

Altered serous levels of monoamine neurotransmitter metabolites in patients with refractory and non-refractory depression
por: Zhang, Guiqing, et al.
Publicado: (2012)

Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels
por: Xue, Cheng, et al.
Publicado: (2023)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017)

Rituximab in Primary Membranous Nephropathy With Severe CKD
por: Naik, Sachin, et al.
Publicado: (2023)

Treatment of exostosin 1-associated membranous lupus nephritis with multiple low doses of rituximab: A case report
por: Li, Ling, et al.
Publicado: (2021)

Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness and renal safety
por: Yu, Xiaojuan, et al.
Publicado: (2017)

Two cases of idiopathic membranous nephropathy treated with rituximab
por: Young Yoon, Jae, et al.
Publicado: (2013)

Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia
por: Šimkovič, Martin, et al.
Publicado: (2015)

Treatment of membranous nephropathy with crescent nephritis by rituximab: A case report
por: Zhang, Fan, et al.
Publicado: (2022)

Clinical Phenotypes and Predictors of Remission in Primary Membranous Nephropathy
por: Jurubiță, Roxana, et al.
Publicado: (2021)

Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab
por: Tendas, Andrea, et al.
Publicado: (2016)

Rituximab-induced serum sickness in the treatment of idiopathic membranous nephropathy
por: Cheong, Jamie, et al.
Publicado: (2018)

Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy
por: Cheungpasitporn, Wisit, et al.
Publicado: (2016)

Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort
por: Gao, Shuang, et al.
Publicado: (2021)

Rituximab in Patients With Primary Membranous Nephropathy With High Immunologic Risk
por: Naik, Sachin, et al.
Publicado: (2023)

The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab
por: Alberici, Federico, et al.
Publicado: (2023)

Case report: Successful treatment of refractory membranous nephropathy with telitacicept
por: Zhang, Lei, et al.
Publicado: (2023)

Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy
por: Stefan, Gabriel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4j8v4sgcfs817fbe2ejdo1kce6